PharmAust Limited (ASX: PAA & PAAOA) is pleased to release its capital raising presentation, focusing on repurposing monepantel for the treatment of ALS, a common neurodegenerative disease. The company recently announced positive top-line results for its Phase 1 MEND study and is planning a Phase 2/3 STRIKE clinical study for accelerated approval by the FDA in 2026. With the neurodegenerative disease market size expected to reach USD 77.82 billion by 2029, there is significant growth potential.

PharmAust has a strong IP position, experienced management team, and diverse investor base. The company has been granted orphan drug designation for monepantel by the FDA, opening up opportunities for tax credits, fee exemptions, and market exclusivity. The upcoming STRIKE study will assess the safety and efficacy of monepantel in ALS patients, with primary endpoints focused on disease progression and survival.

For further details and updates, please refer to our Investor Hub for inquiries and take the opportunity to engage with us. Your questions are important, and we welcome the chance to discuss our progress and future plans in more detail. Feel free to reach out to our Managing Director, Dr. Michael Thurn, for any further information.